Glimepiride 2 mg + Metformin 500 mg + Voglibose 0.2 mg Tablets – GLIMRIL MV2

Glimepiride 2 mg + Metformin 500 mg + Voglibose 0.2 mg Tablets – An effective and convenient solution to manage T2DM.

GLIMRIL MV2 – Glimepiride 2 mg + Metformin 500 mg + Voglibose 0.2 mg Tablets (bilayered) combines three antidiabetic agents— Glimepiride, Voglibose, and Metformin—each with a distinct mechanism of action, offering comprehensive glycemic control in patients with type 2 diabetes mellitus. Glimepiride is a sulfonylurea that stimulates insulin release from the pancreas, Voglibose is an alpha-glucosidase inhibitor that slows carbohydrate absorption in the intestines, and Metformin is a biguanide that improves insulin sensitivity and decreases hepatic glucose production. The extended-release (ER) formulation of Metformin ensures prolonged action, maintaining stable blood glucose levels throughout the day.

Recommended by specialists:
✅Diabetologists – To optimize glycemic control in patients with high post-meal blood sugar spikes.
✅General Physicians (GPs) – For Long term glycemic management and treatment of Type 2 diabetes mellitus.

Key benefits of Glimepiride 2 mg + Metformin 500 mg + Voglibose 0.2 mg Tablets – GLIMRIL MV2:
✅Triple Mechanism of Action: By combining three different antidiabetic agents, the tablet offers enhanced glycemic control, targeting multiple pathways—insulin release, carbohydrate absorption, and insulin sensitivity.
✅Postprandial and Fasting Glucose Control: Voglibose specifically addresses post-meal glucose spikes, while Metformin and Glimepiride help with both fasting and postprandial glucose levels.
✅Extended-Release Metformin: The ER formulation of Metformin ensures sustained action, reducing blood sugar fluctuations and improving patient adherence by requiring only once-daily dosing.

Indications –
✅Type 2 diabetes mellitus
✅Postprandial hyperglycemia
✅Long term glycemic management